Organon Makes Deal With Huya For Access To Chinese Drugs
This article was originally published in The Pink Sheet Daily
While other firms stream to China in search of drug discoveries, Huya aims to bring vetted Chinese drug candidates to the West, CEO Mireille Gingras tells “The Pink Sheet” DAILY.
You may also be interested in...
Akzo Nobel unit will continue development of the Phase III antipsychotic as company moves forward with separation of its coatings and chemical division from its pharma business.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.